Home/Filings/4/0001415889-24-023900
4//SEC Filing

Lizzul Paul F. 4

Accession 0001415889-24-023900

CIK 0001370053other

Filed

Sep 23, 8:00 PM ET

Accepted

Sep 24, 4:18 PM ET

Size

9.2 KB

Accession

0001415889-24-023900

Insider Transaction Report

Form 4
Period: 2024-09-23
Lizzul Paul F.
Chief Medical Officer
Transactions
  • Sale

    Common Stock

    2024-09-23$38.67/sh1,500$58,00515,398 total
  • Exercise/Conversion

    Common Stock

    2024-09-23$18.50/sh+1,500$27,75016,898 total
  • Exercise/Conversion

    Common

    2024-09-231,50085,000 total
    Exercise: $18.50Exp: 2030-07-29Common (1,500 underlying)
Footnotes (3)
  • [F1]The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2024.
  • [F2]The stock option vests and becomes exercisable as to 25% of the shares subject to the option on July 31, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
  • [F3]In addition to the remaining options to purchase 85,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 297,610 shares of common stock, which options vest according to their terms.

Issuer

ANAPTYSBIO, INC

CIK 0001370053

Entity typeother

Related Parties

1
  • filerCIK 0001711462

Filing Metadata

Form type
4
Filed
Sep 23, 8:00 PM ET
Accepted
Sep 24, 4:18 PM ET
Size
9.2 KB